InvestorsHub Logo
Followers 32
Posts 3300
Boards Moderated 0
Alias Born 04/04/2017

Re: None

Friday, 12/08/2017 11:10:10 AM

Friday, December 08, 2017 11:10:10 AM

Post# of 106837
So to recap:

RMAT back on table.

FDA backed off for 3 years.

Q over Q. Y after Y revenue, profit and asset growth.

No toxic financing, and cleaning up balance sheet.


Myocell efficacy results. A clear path for RMAT on this.

Safety results on SVF.

Daily stem cell news gaining hundreds of followers daily...getting the word out.


Totally oversold and undervalued.